Company & Sponsor Intelligence

Creighton University

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials3

Recruiting0

Completed1

Countries1

Therapeutic footprint

autismdepressionparkinsons

Indexed studies

NCT00573547Open Label Trial of Fluoxetine for the Treatment of Depression in Patients With End Stage Renal Disease
depression · United StatesPHASE4

NCT05502055Perspectives on Healthcare Access and Equity of People With Parkinson's Disease Identifying as LGBTQ+
parkinsons · United StatesSUSPENDED

NCT04772898Effectiveness of a 6-week Hippotherapy Program in Children With Autism Spectrum Disorder
autism · United StatesNA

Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →